Tetrac

SKU: orb2901009

Description

Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities.

Key Properties

• CAS Number: 67-30-1
• MW: 747.83
• Purity: >98% (HPLC)
• Formula: C₁₄H₈I₄O₄
• SMILES: OC(=O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1
• Target: Apoptosis
• Solubility: In Vitro: DMSO : 100 mg/mL (133.72 mM; Ultrasonic )

Bioactivity

• In Vivo:
  Tetrac (35 μg; p.o. for 40 days) inhibits tumor inoculation, growth and integrin expression in mice. Animal model: Wild-type male Balb/C mice aged 8 weeks are inoculated with 102B16F10 or B16LS9 cells. Dosage: 35 μg per day. Administration: p.o. (added to the drinking water) daily for 40 days. Result: Delayed the onset of ocular melanoma. Reduced the S-100 and integrin staining level in the B16F10 mice model.
• In Vitro:
  Tetrac (0.01-1 μM; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different K-RAS status. Tetrac (0.1 μM; 30 min) inhibits activation of ERK1/2 in HT-29 and HCT116 cells. Tetrac (0.1 μM; 24 h) inhibits expression of CCND1 and c-Myc, but promotes expression of CASP2 and THBS1.Cell Proliferation Assay Cell line: HT-29 and HCT116 cells. Concentration: 0.01, 0.1, 1 μM Incubation time: 0, 2, 4, 6 days. Result: Induced anti-proliferation of K-RAS wild-type colorectal cancer cells. Western blot analysis. Cell line: HT-29 and HCT116 cells. Concentration: 0.1 μM Incubation time: 30 min. Result: Inhibited constitutively activated ERK1/2, and this inhibition can remove by anti-integrin αvβ3 antibody pretreatment.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Apoptosis